Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.505 USD | +4.81% | +7.23% | -38.39% |
May. 02 | Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis | CI |
Feb. 29 | Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.39% | 317M | |
+20.03% | 46.81B | |
-1.08% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.64% | 26.06B | |
-19.55% | 19.13B | |
+32.60% | 12.39B | |
-0.02% | 12.08B | |
-0.27% | 11.96B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Insider Sold Shares Worth $940,860, According to a Recent SEC Filing